In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea - Archive ouverte HAL
Article Dans Une Revue Molecular Pharmaceutics Année : 2023

In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea

Résumé

Drug permeation across the cornea remains a major challenge due to its unique and complex anatomy and physiology. Static barriers such as the different layers of the cornea, as well as dynamic aspects such as the constant renewal of the tear film and the presence of the mucin layer together with efflux pumps, all present unique challenges for effective ophthalmic drug delivery. To overcome some of the current ophthalmic drug limitations, the identification and testing of novel drug formulations such as liposomes, nanoemulsions, and nanoparticles began to be considered and widely explored. In the early stages of corneal drug development reliable in vitro and ex vivo alternatives, are required, to be in line with the principles of the 3Rs (Replacement, Reduction, and Refinement), with such methods being in addition faster and more ethical alternatives to in vivo studies. The ocular field remains limited to a handful of predictive models for ophthalmic drug permeation. In vitro cell culture models are increasingly used when it comes to transcorneal permeation studies. Ex vivo models using excised animal tissue such as porcine eyes are the model of choice to study corneal permeation and promising advancements have been reported over the years. Interspecies characteristics must be considered in detail when using such models. This review updates the current knowledge about in vitro and ex vivo corneal permeability models and evaluates their advantages and limitations.
Fichier non déposé

Dates et versions

hal-04157238 , version 1 (10-07-2023)

Identifiants

Citer

Inès de Hoon, Rabah Boukherroub, Stefaan de Smedt, Sabine Szunerits, Félix Sauvage. In Vitro and Ex Vivo Models for Assessing Drug Permeation across the Cornea. Molecular Pharmaceutics, 2023, 20 (7), pp.3298-3319. ⟨10.1021/acs.molpharmaceut.3c00195⟩. ⟨hal-04157238⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

More